港股异动丨康宁杰瑞大涨近16%，胃癌新药上市申请获国家药监局受理

Core Viewpoint - Corning Jereh Pharmaceutical-B (9966.HK) experienced a significant intraday increase of nearly 16%, reaching a new high of HKD 12.15 since November 2023, following the acceptance of its new drug application by the National Medical Products Administration for KN026 in combination with chemotherapy for specific cancer patients [1] Company Summary - The company announced a collaboration with Shanghai Jinmant to develop KN026 (Anituzumab Injection) for treating patients with epidermal growth factor receptor 2 positive locally advanced, recurrent, or metastatic gastric/gastroesophageal junction adenocarcinoma who have failed at least one systemic therapy [1]